Drugs / Leqembi
Leqembi cost
lecanemab-irmb · Eisai and Biogen. Every official price for Leqembi, side by side, with who pays it.
Short answer
FDA approved Leqembi (lecanemab-irmb) on Jan 6, 2023. Eisai lists Leqembi at $274.55 per 200 mg/2 mL vial ($686.40 for a 500 mg/5 mL vial), as of October 5, 2026 (Eisai price list). Medicare Part B pays up to $1.361 per mg for Leqembi given by IV infusion (October 1, 2026 to December 31, 2026).412
Source: FDA, Eisai and CMS · checked Oct 25, 2026
Leqembi: the official numbers, by situation
| Price | Amount | Whose price, and who it applies to | Date |
|---|---|---|---|
| List price per 200 mg/2 mL vial ($686.40 for a 500 mg/5 mL vial) | $274.55–$686.401 | Eisai's price to wholesalers (WAC). Most people don't pay it directly. | October 5, 2026 (Eisai price list) |
| Medicare Part B payment limit per mg, Leqembi given by IV infusion | $1.3612 | What Medicare pays when the drug is paid under Part B (for example, given in a clinic). CMS lists Part B coinsurance for this code as 20%. | October 1, 2026 – December 31, 2026 |
None of these is your price at the counter: that depends on how you pay. Details and sources for each number are further down.
FDA approval
- Approved by the FDA on Jan 6, 2023 as a new drug (lecanemab-irmb).4
- FDA-approved use on the approval date, in FDA's words: "To treat Alzheimer’s disease."4 The current label may list more uses; ask your doctor or pharmacist what applies to you.
Every official price
| Price | Amount | What it is | Date |
|---|---|---|---|
| Maker's list price (WAC) | $274.55–$686.401 | Per 200 mg/2 mL vial ($686.40 for a 500 mg/5 mL vial). The price the maker charges wholesalers; most people do not pay it directly. | October 5, 2026 (Eisai price list) (checked Oct 25, 2026) |
| Maker's list price Leqembi IV, 200 mg/2 mL vial | $274.551 | From the maker's price list. | October 5, 2026 (Eisai price list) |
| Maker's list price Leqembi IV, 500 mg/5 mL vial | $686.401 | From the maker's price list. | October 5, 2026 (Eisai price list) |
| Maker's list price Leqembi Iqlik (under the skin), 360 mg/1.8 mL autoinjector | $3851 | From the maker's price list. | October 5, 2026 (Eisai price list) |
| Maker's list price Leqembi Iqlik, 250 mg/1.25 mL, pack of 2 autoinjectors | $7701 | From the maker's price list. | October 5, 2026 (Eisai price list) |
| Medicare Part B payment limit Leqembi given by IV infusion (lecanemab-irmb) · HCPCS J0174 | $1.3612 | Per 1 mg, when given in a clinic or hospital outpatient setting and paid under Part B. CMS lists Part B coinsurance for this code as 20%. | October 1, 2026 – December 31, 2026 |
| Pharmacy acquisition cost (NADAC) | Not listed | This drug is not in the NADAC survey, which covers drugs dispensed by retail pharmacies. | — |
These are prices the drug company, Medicare and pharmacies use. What you pay depends on your coverage; see below. CMS notes that a code's presence in its payment file does not by itself mean Medicare covers the drug.3
Leqembi cost per infusion and per year
Leqembi by IV is dosed by body weight: 10 mg per kg, every 2 weeks to start. At Eisai's list prices, that is $960.95 per infusion for a 70 kg (154 lb) person, or $24,984.70 for 26 infusions in a year.16
| Body weight | Dose | Vials | Per infusion | Year, every 2 weeks | Year, every 4 weeks |
|---|---|---|---|---|---|
| 50 kg (110 lb) | 500 mg | 1 × 500 mg | $686.40 | $17,846.40 | $8,923.20 |
| 70 kg (154 lb) | 700 mg | 1 × 200 mg + 1 × 500 mg | $960.95 | $24,984.70 | $12,492.35 |
| 90 kg (198 lb) | 900 mg | 2 × 200 mg + 1 × 500 mg | $1,235.50 | $32,123 | $16,061.50 |
| 100 kg (220 lb) | 1,000 mg | 5 × 200 mg | $1,372.75 | $35,691.50 | $17,845.75 |
Weights chosen so the dose fills whole vials. Vials are the cheapest mix of 200 mg and 500 mg.
After 18 months, the label allows staying on every 2 weeks or moving to a maintenance dose every 4 weeks.6
Leqembi Iqlik, under the skin once a week: 500 mg (two 250 mg injections) at $770 a week to start ($40,040 for 52 weeks); 360 mg maintenance at $385 a week ($20,020 for 52 weeks).16
With Medicare Part B, the payment limit for a 700 mg IV dose (HCPCS J0174) is $952.70; 20% coinsurance on that is $190.54 per infusion, before the Part B deductible and without a Medigap or Medicare Advantage plan.2
List price read on the maker's page Oct 25, 2026. List price is what the maker charges wholesalers, not what you pay. These figures are for the medicine only: the clinic's infusion, MRI and PET charges are extra. Your doctor decides the dose and schedule.
Kisunla vs Leqembi: first-year list price
- Kisunla: $33,648.54, 13 infusions, one every 4 weeks.
- Leqembi: $24,984.70, 26 infusions, one every 2 weeks, for a 70 kg (154 lb) person.
Medicine only, at each maker's list price, on the label's starting schedule. A price comparison, not a comparison of how well they work.
With Medicare
- When given in a clinic and paid under Medicare Part B, Medicare's payment is based on the limit above, and CMS lists the coinsurance as 20%.2 A Medicare Supplement (Medigap) policy or Medicare Advantage plan changes what you pay.
- CMS, National Coverage Determination 200.3 (anti-amyloid antibodies for Alzheimer's disease): "Effective April 7, 2022, the Centers for Medicare & Medicaid Services (CMS) covers Food and Drug Administration (FDA) approved monoclonal antibodies directed against amyloid for the treatment of AD when furnished in accordance with Section B under coverage with evidence development (CED) for patients who have a clinical diagnosis of mild cognitive impairment (MCI) due to AD or mild AD dementia, both with confirmed presence of amyloid beta pathology consistent with AD."5
- Higher income? Part B and Part D premiums can include IRMAA: IRMAA brackets.
With commercial insurance or no insurance
- What you pay depends on your plan's copay or coinsurance. The maker lists its savings and support options here: Eisai: LEQEMBI patient support. We link to it but do not copy its terms.
Which drug, which dose, and whether to start, stop or switch are medical decisions. Ask your doctor or pharmacist.
Get an email when a price or rule changes
Only when an official GLP-1 self-pay price or a Medicare or Medicaid rule changes, at most once a week, with the official source for every change.
Official sources for this page (6)
“Eisai Inc Price List, Effective October 5, 2026: Leqembi 200mg/2ml (100mg/mL) 1 Vial $274.55; Leqembi 500mg/5ml (100mg/mL) 1 Vial $686.40; Leqembi 360 mg/1.8 mL (200 mg/mL) 1 single-dose prefilled autoinjector $385.00; LEQEMBI 250 mg/1.25 mL (200 mg/mL) 2 single-dose prefilled autoinjectors $770.00”
Eisai: Leqembi pricing (entered by hand) · as of Oct 25, 2026- CMS: Medicare Part B Payment Limit File (quarterly ASP pricing) · as of Oct 23, 2026
“The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate whether Medicare covers a drug.”
CMS: Medicare Part B Payment Limit File (quarterly ASP pricing) · as of Oct 23, 2026“Leqembi lecanemab-irmb 1/6/2023 To treat Alzheimer’s disease”
FDA: Novel Drug Approvals for 2023 · as of Oct 25, 2026“Effective April 7, 2022, the Centers for Medicare & Medicaid Services (CMS) covers Food and Drug Administration (FDA) approved monoclonal antibodies directed against amyloid for the treatment of AD when furnished in accordance with Section B under coverage with evidence development (CED) for patients who have a clinical diagnosis of mild cognitive impairment (MCI) due to AD or mild AD dementia, both with confirmed presence of amyloid beta pathology consistent with AD.”
“Recommended starting dosage: Intravenous infusion: 10 mg/kg once every 2 weeks administered after dilution as an intravenous infusion over approximately one hour. ( 2.2 , 2.5 ) Subcutaneous injection: 500 mg administered once a week using the LEQEMBI IQLIK autoinjector. ( 2.2 , 2.6 ). After 18 months, continue treatment with the starting dosage or transition to an intravenous or subcutaneous maintenance dosage. (2.2) Recommended maintenance dosage: Intravenous infusion: 10 mg/kg once every 4 weeks ( 2.2 , 2.5 ) Subcutaneous injection: 360 mg administered once a week using the LEQEMBI IQLIK autoinjector”